MedPath

A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

Terminated
Conditions
Atopic Dermatitis
Registration Number
NCT00475605
Lead Sponsor
LEO Pharma
Brief Summary

This is an observational study to assess the long-term safety of Protopic® Ointment for the treatment of atopic dermatitis. Patients whose ages are/were \< 16 years at the time of first tacrolimus ointment exposure are eligible to participate. No drug is distributed during this observational trial.

Detailed Description

Data will be collected at enrollment and every 6 months thereafter either by interview, Internet, or physician office visit. Each subject will be followed for 10 years in this study.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
8071
Inclusion Criteria
  • Subjects who first used Protopic® 0.03% or 0.1% before they were sixteen years of age and were treated for at least 6 weeks for the treatment of Atopic dermatitis may enroll into the study.
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Occurrence of systemic or cutaneous malignancy10 years

Standardised Incidence Ratio (versus population cancer rates)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (301)

Shelby Dermatology

🇺🇸

Alabaster, Alabama, United States

Pediatric Care Center of NE Alabama

🇺🇸

Anniston, Alabama, United States

Total Skin and Beauty Dermatology Center

🇺🇸

Birmingham, Alabama, United States

Metro Pediatrics, P.C

🇺🇸

Birmingham, Alabama, United States

Pediatric & Adult Asthma and Allergy, P.C.

🇺🇸

Birmingham, Alabama, United States

Skin Wellness Center of Alabama

🇺🇸

Birmingham, Alabama, United States

Southview Dermatology

🇺🇸

Birmingham, Alabama, United States

Ruth A Yates

🇺🇸

Huntsville, Alabama, United States

Alliance Dermatology

🇺🇸

Phoenix, Arizona, United States

Derma

🇺🇸

Phoenix, Arizona, United States

Scroll for more (291 remaining)
Shelby Dermatology
🇺🇸Alabaster, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.